The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
List view / Grid view
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
Researchers reveal drugs inhibiting Neuropilin-1 (NRP1), a protein expressed on T cells, could improve the efficacy of immunotherapies.
A new study conducted in Israel suggests that T cells’ ability to destroy skin cancer increases in the absence of T-cell regulators called SLAMF6.
Researchers have developed a compound that can be activated with infrared light to kill cancer cells in model tumours, advancing the possibilities of photodynamic therapy.
A study has shown that type II kinase inhibitors targeting CDK8 alone are ineffective because mutations leave them inactive, suggesting future therapies should target CDK8 in complex.
A study has shown that long non-coding RNA called DIRC3 can block melanoma growth and could be used to identify new targets for skin cancer therapies.
A new therapeutic route for combatting treatment-resistant cancer has been identified with the discovery that melanoma cells fight anti-cancer drugs by changing their internal skeleton.
A library of products derived from more than 10,000 fungi has been established which could lead to the discovery of new drugs.
It has been discovered that papillomaviruses induce immunity that protects patients, which could lead to a novel method for preventing skin cancer using a vaccine based on T cells.
A study has revealed a drug target for skin cancers which regulates the differentiation of cells and the roles they conduct in the body.
Researchers have reported a potential new role for some bacteria on the skin, protecting against cancer...
New technology being developed by researchers is using artificial intelligence to help detect melanoma skin cancer earlier...